The Claim
Patients with Graves' disease and orbitopathy have higher anti-nuclear antibody titers (1:160) compared to Graves' disease patients without orbitopathy, although the difference is not statistically significant (P=0.059).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with Graves' disease, those who have eye complications tend to have higher levels of anti-nuclear antibodies than those without eye complications, but the difference is not statistically confirmed.
See the scientific wording
Higher anti-nuclear antibody titers (1:160) are more common in Graves' disease patients with orbitopathy than in those without, though the difference is not statistically significant (P=0.059), suggesting a possible dose-response relationship that requires further validation.
Higher levels of anti-nuclear antibodies in the blood trigger an increase in regulatory T cells, which calm down the immune attack on the tissues behind the eyes, leading to less swelling and damage in Graves' orbitopathy.
What the research says
1 studyStudy: Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
People with Graves' disease who have eye problems were a bit more likely to have higher levels of a certain antibody, but the difference wasn't strong enough to be sure — so scientists say we need to study it more.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.